SEC-TID: A Label-Free Method for Small-Molecule Target Identification

• Published in: Journal of biomolecular screening Vol. 19; no. 6; pp. 917 - 927
• Main Authors: Salcius, Michael, Bauer, Andras J, Hao, Qin, Li, Shu, Tutter, Antonin, Raphael, Jacob, Jahnke, Wolfgang, Rondeau, Jean-Michel, Bourgier, Emmanuelle, Tallarico, John, Michaud, Gregory A
• Format: Journal Article
• Language: English
• Published: United States 01.07.2014
• Subjects: Animals; Calorimetry; Catalytic Domain; Cattle; Chromatography, Gel - methods; Chromatography, Liquid; Crystallography, X-Ray; Databases, Protein; Drug Discovery; Fluorometry; Humans; Ligands; Macromolecular Substances; Magnetic Resonance Spectroscopy; Mass Spectrometry - methods; Nucleic Acids - chemistry; Proteins - chemistry; Proteomics - methods; Small Molecule Libraries - chemistry; Xanthones - chemistry; liquid chromatography–mass spectrometry; nucleic acids; proteins; size-exclusion chromatography; small molecules; target identification
• ISSN: 2472-5552; 1552-454X
• DOI: 10.1177/1087057114522691

Bioactive small molecules are an invaluable source of therapeutics and chemical probes for exploring biological pathways. Yet, significant hurdles in drug discovery often come from lacking a comprehensive view of the target(s) for both early tool molecules and even late-stage drugs. To address this challenge, a method is provided that allows for assessing the interactions of small molecules with thousands of targets without any need to modify the small molecule of interest or attach any component to a surface. We describe size-exclusion chromatography for target identification (SEC-TID), a method for accurately and reproducibly detecting ligand-macromolecular interactions for small molecules targeting nucleic acid and several protein classes. We report the use of SEC-TID, with a library consisting of approximately 1000 purified proteins derived from the protein databank (PDB), to identify the efficacy targets tankyrase 1 and 2 for the Wnt inhibitor XAV939. In addition, we report novel interactions for the tumor-vascular disrupting agent vadimezan/ASA404 (interacting with farnesyl pyrophosphate synthase) and the diuretic mefruside (interacting with carbonic anhydrase XIII). We believe this method can dramatically enhance our understanding of the mechanism of action and potential liabilities for small molecules in drug discovery pipelines through comprehensive profiling of candidate druggable targets.